News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website


Musella Foundation Awards Brain Tumor Research Grant!

Al's Comment:

 This is a fascinating new approach.  Instead of targeting one or two specific pathways that drive tumor growth, this one covers over 20 pathways. Hopefully it will not only work, but will also be much harder for the tumor to become resistent and evolve around it!

With the design of this trial, we should know pretty quickly if the concept works.  It is for newly diagnosed high grade glioma patients, and is only being done at the Cleveland Clinic in Ohio.  IF this shows good results, I am sure it will quickly expand to many major centers.


Posted on: 02/03/2014

Musella Foundation Awards Brain Tumor Research Grant!
The Musella Foundation For Brain Tumor Research & Information, Inc awarded a $50,000 grant today to Dr. Manmeet Ahluwalia, from the Cleveland Clinic, Ohio,  for his project: "Phase 1 clinical trial of Ganetespib with Radiation and Temozolomide in Patients With Newly Diagnosed High Grade Glioma". 
Gantespib is an investigational, synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 is a molecular chaperone required for the proper maturation and activation of numerous client proteins. Many of these Hsp90 client proteins play critical roles in cell growth, differentiation, and survival. Relative to normal cells, cancer cells are more reliant on elevated levels of the active form of Hsp90 and, as such, appear to be selectively sensitive to Hsp90 inhibitors, including ganetespib. Ganetespib binds to and inhibits Hsp90, resulting in the proteasomal degradation of oncogenic client proteins, the inhibition of cell proliferation and the elevation of heat shock protein 72 (Hsp72); it may inhibit the activity of multiple kinases, such as c-Kit, EGFR, and Bcr-Abl, which as client proteins depend on functional HsP90 for maintenance. Read more about Gantespib at  First watch the video on that page, then click on Pipeline / Gantespib to read about all of the pathways that Gantespib can inhibit.
The Musella Foundation For Brain Tumor Research & Information, Inc is a 501(c)(3) nonprofit public charity dedicated to helping brain tumor patients through support, education, advocacy and raising money for brain tumor research.
Al Musella, DPM – President
Musella Foundation


Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557